Skip to main content

and
  1. Article

    Open Access

    The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

    Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibit...

    Shiloh M Martin, Eric Churchill, Hayes McKnight in Journal of Hematology & Oncology (2011)

  2. Article

    Open Access

    The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone

    Previous studies have shown that bispecific antibodies that target both CD20 and CD22 have in vivo lymphomacidal properties. We developed a CD20-CD22 bispecific antibody (Bs20x22) from anti-CD20 and the anti-C...

    Joseph M. Tuscano, Yunpeng Ma, Shiloh M. Martin in Cancer Immunology, Immunotherapy (2011)

  3. Article

    Open Access

    Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

    Non-Hodgkin’s lymphoma (NHL) is the sixth most common cause of cancer deaths in the U.S. Most NHLs initially respond well to chemotherapy, but relapse is common and treatment is often limited due to the toxici...

    Robert T. O’Donnell, Shiloh M. Martin, Yunpeng Ma in Investigational New Drugs (2010)

  4. No Access

    Article

    Imaging and Pharmacokinetics of 64Cu-DOTA-HB22.7 Administered by Intravenous, Intraperitoneal, or Subcutaneous Injection to Mice Bearing Non-Hodgkin’s Lymphoma Xenografts

    The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu-DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), a...

    Shiloh M. Martin, Robert T. O’Donnell, David L. Kukis in Molecular Imaging and Biology (2009)